Acadia Q2 NUPLAZID sales $134.6M (+17% YoY); NDA filed for trofinetide in Rett syndrome

ACADIA PHARMACEUTICALS INC

2022-Q2 EPS reported -$0.91 revenue$134,563,000

Q2 net loss $34.0M ($0.21/share) vs $43.9M loss in Q2 2021; six-month loss $147.1M.
R&D expense $75.6M vs $56.9M YoY; SG&A $89.9M vs $96.8M on lower promo costs.
NDA submitted to FDA for trofinetide for Rett syndrome; CRL received for pimavanserin in Alzheimer's psychosis.
Discontinued development of ACP-044 (pain) and ACP-319 (M1 PAM) based on data review.
2022 NUPLAZID revenue guidance narrowed to $510-540M from $510-560M; R&D guidance reduced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.